Analysed ZENTALIS PHARMACEUTICALS INC (ZNTL:NASDAQ) News Sources
Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer
05-05-2026
yahoo.com
Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026
17-07-2026
yahoo.com
Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
17-08-2026
yahoo.com
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01-09-2026
yahoo.com
Zentalis Pharmaceuticals Shares Rise After Leerink Assumes Coverage With Outperform Rating
05-10-2026
advfn.com
Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract
18-10-2026
yahoo.com
What is the current price of ZENTALIS PHARMACEUTICALS INC (ZNTL:NASDAQ)?
The current price of ZENTALIS PHARMACEUTICALS INC (ZNTL:NASDAQ) is $1.99.
ZENTALIS PHARMACEUTICALS INC (ZNTL:NASDAQ) absolute price change since previous trading day?
The absolute price change of ZENTALIS PHARMACEUTICALS INC (ZNTL:NASDAQ) since the previous trading day is $-0.07.
ZENTALIS PHARMACEUTICALS INC (ZNTL:NASDAQ) percentage price change since previous trading day?
The percentage price change of ZENTALIS PHARMACEUTICALS INC (ZNTL:NASDAQ) since the previous trading day is -3.3981%.
What is the most recent average sentiment score for ZENTALIS PHARMACEUTICALS INC (ZNTL:NASDAQ)?
The most recent average sentiment score for ZENTALIS PHARMACEUTICALS INC (ZNTL:NASDAQ) is 86 out of 100.
What is the most recent average sentiment for ZENTALIS PHARMACEUTICALS INC (ZNTL:NASDAQ)?
The most recent sentiment for ZENTALIS PHARMACEUTICALS INC (ZNTL:NASDAQ) is .
SEC-8K** Filing Available For ZENTALIS PHARMACEUTICALS INC (ZNTL:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.